Clinical and molecular features of papillary thyroid cancer in adolescents and young adults

Age disparities in thyroid cancer incidence and outcome among adolescents and young adults (AYAs) with thyroid cancer are under reported. In this study, the authors compared the molecular and clinical features of papillary thyroid cancer (PTC) in AYAs with the same features among patients in other age groups.

[1]  M. Nikiforova,et al.  Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. , 2009, The Journal of clinical endocrinology and metabolism.

[2]  M. Haymart.  Understanding the relationship between age and thyroid cancer. , 2009, The oncologist.

[3]  A. El‐Naggar,et al.  High Rate of BRAF and RET/PTC Dual Mutations Associated with Recurrent Papillary Thyroid Carcinoma , 2009, Clinical Cancer Research.

[4]  A. Gill,et al.  Increasing incidence of thyroid cancer is due to increased pathologic detection. , 2008, Surgery.

[5]  N. Hasimoto,et al.  Potential for Differential Diagnosis of Autoimmune Pancreatitis and Pancreatic Cancer Using Carbonic Anhydrase II Antibody , 2008, Pancreas.

[6]  Yong-xue Zhu,et al.  Incidentally simultaneous occurrence of RET/PTC, H4-PTEN and BRAF mutation in papillary thyroid carcinoma. , 2008, Cancer letters.

[7]  A. Bleyer,et al.  The challenges of clinical trials for adolescents and young adults with cancer , 2008, Pediatric blood & cancer.

[8]  David M. Thomas,et al.  The distinctive biology of cancer in adolescents and young adults , 2008, Nature Reviews Cancer.

[9]  F. Basolo,et al.  Papillary thyroid cancer: Pathological parameters as prognostic factors in different classes of age , 2008, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[10]  Electron Kebebew,et al.  The Prevalence and Prognostic Value of BRAF Mutation in Thyroid Cancer , 2007, Annals of surgery.

[11]  F. S. Ambesi-Impiombato,et al.  Differential expression of the components of the plasminogen activating system in human thyroid tumour derived cell lines and papillary carcinomas. , 2006, European journal of cancer.

[12]  E. Kebebew,et al.  Diagnostic and extent of disease multigene assay for malignant thyroid neoplasms , 2006, Cancer.

[13]  Louise Davies,et al.  Increasing incidence of thyroid cancer in the United States, 1973-2002. , 2006, JAMA.

[14]  Q. Duh,et al.  Diagnostic and prognostic value of angiogenesis-modulating genes in malignant thyroid neoplasms. , 2005, Surgery.

[15]  M. Kralik,et al.  Urokinase-type plasminogen activator and its inhibitor in thyroid neoplasms: a cytosol study , 2005, Wiener klinische Wochenschrift.

[16]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Q. Duh,et al.  ECM1 and TMPRSS4 Are Diagnostic Markers of Malignant Thyroid Neoplasms and Improve the Accuracy of Fine Needle Aspiration Biopsy , 2005, Annals of surgery.

[18]  J. Sandbank,et al.  Differentiated Thyroid Carcinoma in Children and Young Adults: Evaluation of Response to Treatment , 2005, Clinical nuclear medicine.

[19]  S. Parkkila,et al.  Expression of a novel carbonic anhydrase, CA XIII, in normal and neoplastic colorectal mucosa , 2005, BMC Cancer.

[20]  D. Das.  Age of Patients with Papillary Thyroid Carcinoma: Is It a Key Factor in the Development of Variants? , 2005, Gerontology.

[21]  Q. Chu,et al.  Overexpression of Urinary Plasminogen Activator (uPA) Protein and mRNA in Thyroid Carcinogenesis , 2004, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[22]  C. Ris-Stalpers,et al.  Genes differentially expressed in thyroid carcinoma identified by comparison of SAGE expression profiles , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[23]  R. Camp,et al.  ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M. Daly,et al.  PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes , 2003, Nature Genetics.

[25]  H. Rabes,et al.  High prevalence of RET rearrangement in thyroid tumors of children from Belarus after the Chernobyl reactor accident. , 1995, Oncogene.

[26]  E. Mazzaferri.  Increasing Incidence of Thyroid Cancer in the United States, 1973–2002Davies L, Welch HG (Dept of Veterans Affairs Med Ctr, White River Junction, Vt; Darmouth Med School, Hanover, NH) JAMA 295:2164–2167, 2006§ , 2007 .

[27]  R. Görges,et al.  Prognostic value of c-erbB-2 expression in papillary thyroid carcinoma , 2005, Nuklearmedizin.